Nvidia disclosed in recent regulatory filings that it had fully exited its roughly two‑year, 7.71 million‑share investment in Recursion Pharmaceuticals, while Cathie Wood’s ARK Invest simultaneously ...

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...

Major investors Nvidia and Novo Holdings A/S have fully exited their positions in Recursion Pharmaceuticals (NasdaqGS:RXRX), signaling a shift in institutional backing. Recursion has acquired full ...

FDA truncates drug approval process; Makary pushes for more OTC drugs; Inside the rocky ride for Recursion Pharmaceuticals.

The past is fast losing its reliability as a guide to the future in an age of exponentially evolving AI. As error rates drop ...

Dead languages aren't as unimportant as they seem, because learning Latin, Sanskrit and Ancient Greek will make coding easier ...

The India AI Impact Summit 2026 in New Delhi brings together global political leaders, technology giants, startups, and ...

An earlier 13F filing showed that the chipmaker held 7,716,050 shares of Applied Digital as of the end of September. ・Nvidia ...

If you were looking for me last Saturday evening, you’d have found me at the Irene and Alan Wurtzel Theater for the TIMARA faculty recital, titled “Signal: Noise.” The Wurtzel Theater’s vibe was ...

Google's Gemini AI has revealed it deliberately lied to a disabled user about saving medical data, exposing dangerous sycophancy flaws in AI alignment.

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...